Earnings on Tap: Chevron, Merck
Rising oil prices could boost Chevron earnings, and Merck's operating costs might fall.
Rising oil prices could boost Chevron earnings, and Merck's operating costs might fall.
Oil major Chevron (CVX), which is slated to announce quarterly results before the stock market opens Friday, is expected to post earnings of $3.51 per share, according to a consensus of Wall Street analysts, compared with $2.70 per share in the prior-year quarter.
The firm, in a recent investor update, said its production rate had come down in the quarter, but higher oil and natural gas prices would likely offset any impact on profits. However, analysts might want to know about the progress of production ramp-up at new wells to make up for the shortfall of output from older projects.
Investors will also likely focus on whether the company is on track for its 1% increase in production for this year.
Also posting earnings before the bell is Merck (MRK). Analysts, on average, expect the firm to clock EPS of $0.95, rising from $0.24 per share in the same quarter last year.
Company-watchers may seek updates on the launch of the drug Victrelis (boceprevir) for hepatitis C, which the Food and Drug Administration approved in May. The potential success of Victrelis is significant for Merck, with blockbuster asthma-drug Singulair poised to lose patent in 2012 and after the patent loss of hypertension drugs Cozaar and Hyzaar in 2010.
The firm's operating costs might also be eyed and any reduction would be seen as progress toward achieving greater synergies from its 2009 acquisition of Schering-Plough.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.